Breaking News Instant updates and real-time market news.

EDIT

Editas Medicine

$13.81

0.55 (4.15%)

04:55
10/19/16
10/19
04:55
10/19/16
04:55

Editas Medicine management to meet with JPMorgan

Meetings to be held in Los Angeles on October 18 and in San Francisco/San Mateo on October 19 hosted by JPMorgan.

  • 19

    Oct

EDIT Editas Medicine
$13.81

0.55 (4.15%)

02/29/16
02/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Brian Ossenbeck initiated a cautious outlook for the North American truckload sector, saying he believes "tepid" freight demand and a lack of a boost to consumer spending from low gas prices will lead the first contraction in realized revenue per loaded mile since 2007. Ossenteck initiated Werner (WERN) with an Overweight rating due to expectations that its diversification will drive a re-rating of its shares. The analyst set a Neutral rating on Swift Transport (SWFT) and Ryder (R), and an Underweight rating on Heartland Express (HTLD) and Knight Transportation (KNX). 2. Editas Medicine (EDIT) initiated with an Outperform at Cowen and JMP Securities, and a Neutral at JPMorgan. Cowen cited the company's "world-class expertise" in CRISPR, which will enable the development of a broad pipeline. JPMorgan analyst Cory Kasimov added that the company's CRISPR gene editing platform has the potential to be a game changer, but that it has "limited value-inflecting news" likely to come in 2016. 3. BeiGene (BGNE) initiated with an Outperform at Cowen citing the proof-of-concept data on each of four clinical candidates and expects to monetize those assets on the global stage. The company was also initiated with an Overweight and a Buy at Morgan Stanley and Goldman, respectively. 4. Nielsen (NLSN) initiated with a Buy at Jefferies by analyst Ryan Cary, who said the company is well positioned to benefit from demand for cross-platform viewership measurement and greenfield in emerging markets provides protection against macro headwinds. 5. Square (SQ) initiated with a Sector Weight at Pacific Crest by analyst Josh Beck, who said his optimism is balanced by the market's high expectations for execution, the uncertain regulatory environment for SMB lending, and software initiatives. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
06/02/16
JEFF
06/02/16
INITIATION
Target $35
JEFF
Hold
Editas Medicine initiated with a Hold at Jefferies
Jefferies analyst Gena Wang started Editas Medicine with a Hold rating and $35 price target.
06/21/16
JANY
06/21/16
NO CHANGE
Target $48
JANY
Buy
Janney says Editas may be weak after UPenn scientists first to Cas9 RAC
Janney Capital analyst Roy Buchanan noted that members of the NIH's Recombinant DNA Advisory Committee, or RAC, were supportive of a phase 1 trial proposed by scientists at the University of Pennsylvania to test the use of CRISPR-Cas9 to create genetically altered immune cells to attack cancer. Buchanan noted shares of Editas Medicine may be impacted since the company will not be the first to the Cas9 RAC, as had been expected, but he noted this academic study will address a limited patient population, adding that "there is plenty of CAR-T/TCR space left to operate". The firm has a Buy rating and $48 fair value estimate on Editas shares.
08/10/16
JEFF
08/10/16
UPGRADE
Target $35
JEFF
Buy
Editas Medicine upgraded to Buy from Hold at Jefferies
Jefferies analyst Gena Wang upgraded Editas Medicine to Buy saying the recent pullback in the shares provides an opportunity to own the company's "transformative CRIPSR technology." The analyst keeps a $35 price target for the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.